A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336
This study is recruiting at 8 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ulcerative Colitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Genentech, Inc.
- Last updated on ClinicalTrials.gov
- September 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Gastro Care Institute · Lancaster, CA
- Medical Associates Research Group, Inc. · San Diego, CA
Colorado · 1
- Peak Gastroenterology Associates · Colorado Springs, CO
Florida · 1
- Clinical Research of Osceola, LLC · Kissimmee, FL
Illinois · 1
- University of Chicago Medical Center · Chicago, IL
New York · 1
- Intercity Gastroenterology · Fresh Meadows, NY
North Carolina · 1
- Monroe Biomedical Research · Monroe, NC
Utah · 1
- University of Utah Hospitals & Clinics · Salt Lake City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.